Novel vaccines protecting against the development of allergic disorders: A double-edged sword?

Current Opinion in Immunology

Volumn 14, Issue 5, 2002, Pages 633-643

  Erb, Klaus J ^a   Wohlleben, Gisela ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIALLERGIC AGENT; DNA VACCINE;

ALLERGIC DISEASE; DISEASE SEVERITY; HELPER CELL; HUMAN; INCIDENCE; NONHUMAN; REVIEW; SIDE EFFECT; TH1 CELL; TH2 CELL; VACCINATION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; HUMANS; HYPERSENSITIVITY; OLIGODEOXYRIBONUCLEOTIDES; TH1 CELLS; VACCINES; VACCINES, DNA;

EID: 0036774987     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(02)00385-0     Document Type: Review

References (96)

1. Romagnani S. Cytokines and chemoattractants in allergic inflammation. Mol Immunol. 38:2002;881-885.
2. Wohlleben G., Erb K.J. Atopic disorders: a vaccine around the corner? Trends Immunol. 22:2001;618-626. This review focuses on the use of anti-allergy vaccines based on the induction of Th1 responses. It is a detailed, concise and up-to-date review of this topic.
3. Herz U., Lacy P., Renz H., Erb K. The influence of infections on the development and severity of allergic disorders. Curr Opin Immunol. 12:2000;632-640.
4. Cohn L., Homer R.J., Niu N., Bottomly K. T helper 1 cells and interferon gamma regulate allergic airway inflammation and mucus production. J Exp Med. 190:1999;1309-1318.
5. Huang T.J., MacAry P.A., Eynott P., Moussavi A., Daniel K.C., Askenase P.W., Kemeny D.M., Chung K.F. Allergen-specific Th1 cells counteract efferent Th2 cell-dependent bronchial hyperresponsiveness and eosinophilic inflammation partly via IFN-gamma. J Immunol. 166:2001;207-217. This study demonstrates that syngenic allergen-specific Th1 cells transferred into rats inhibited the development of pulmonary Th2 responses induced by the transfer of allergen specific Th2 cells. The effect was not observed when IFN-γ was neutralised, thereby supporting the view that allergen-specific Th1 cells can counteract Th2 cell-mediated inflammation by secreting IFN-γ.
6. Major T., Wohlleben G., Reibetanz B., Erb K.J. Application of heat killed Mycobacterium bovis-BCG into the lung inhibits the development of allergen-induced Th2 responses. Vaccine. 20:2002;1532-1540. This study illustrated that, in a similar way to live BCG, heat-killed BCG applied i.n. into mice inhibited the development of allergen-induced airway eosinophilia for up to two months after the application. In addition, evidence is provided that treatment with live or heat-killed BCG inhibited the efficient recruitment of Th2 cells into the airways.
7. Erb K.J., Holloway J.W., Sobeck A., Moll H., Le Gros G. Infection of mice with Mycobacterium bovis-Bacillus Calmette-Guerin (BCG) suppresses allergen-induced airway eosinophilia. J Exp Med. 187:1998;561-569.
8. Herz U., Gerhold K., Gruber C., Braun A., Wahn U., Renz H., Paul K. BCG infection suppresses allergic sensitization and development of increased airway reactivity in an animal model. J Allergy Clin Immunol. 102:1998;867-874.
9. Su Y.C., Peng H.J., Wang S.R., Han S.H., Tsai J.J. Effects of BCG on ovalbumin-induced bronchial hyperreactivity in a guinea pig asthma model. J Microbiol Immunol Infect. 34:2001;25-34.
10. Hopfenspirger M.T., Agrawal D.K. Airway hyperresponsiveness, late allergic response, and eosinophilia are reversed with mycobacterial antigens in ovalbumin-presensitized mice. J Immunol. 168:2002;2516-2522. The authors report that the application of BCG and M. vaccae was able to reduce allergic inflammation in mice that were presensitised and rechallenged with allergen. The use of BCG was more effective than M. vaccae. This is the first report indicating that the application of BCG is also effective in inhibiting already established Th2 responses.
11. Wang C.C., Rook G.A. Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccae. Immunology. 93:1998;307-313.
12. lo T cells, IL-10 and TGF-β.
13. Janssen R., Kruisselbrink A., Hoogteijling L., Lamb J.R., Young D.B., Thole J.E. Analysis of recombinant mycobacteria as T helper type 1 vaccines in an allergy challenge model. Immunology. 102:2001;441-449.
14. Yeung V.P., Gieni R.S., Umetsu D.T., DeKruyff R.H. Heat-killed Listeria monocytogenes as an adjuvant converts established murine Th2-dominated immune responses into Th1-dominated responses. J Immunol. 161:1998;4146-4152.
15. Murosaki S., Yamamoto Y., Ito K., Inokuchi T., Kusaka H., Ikeda H., Yoshikai Y. Heat-killed Lactobacillus plantarum L-137 suppresses naturally fed antigen-specific IgE production by stimulation of IL-12 production in mice. J Allergy Clin Immunol. 102:1998;57-64.
16. Hansen G., Yeung V.P., Berry G., Umetsu D.T., DeKruyff R.H. Vaccination with heat-killed Listeria as adjuvant reverses established allergen-induced airway hyperreactivity and inflammation: role of CD8+ T cells and IL-18. J Immunol. 164:2000;223-230.
17. Vannier E., Lefort J., Lellouch-Tubiana A., Terlain B., Vargaftig B.B. Lipopolysaccharide from Escherichia coli reduces antigen-induced bronchoconstriction in actively sensitized guinea pigs. J Clin Invest. 87:1991;1936-1944.
18. Tulic M.K., Wale J.L., Holt P.G., Sly P.D. Modification of the inflammatory response to allergen challenge after exposure to bacterial lipopolysaccharide. Am J Respir Cell Mol Biol. 22:2000;604-612.
19. Tulic M.K., Knight D.A., Holt P.G., Sly P.D. Lipopolysaccharide inhibits the late-phase response to allergen by altering nitric oxide synthase activity and interleukin-10. Am J Respir Cell Mol Biol. 24:2001;640-646.
20. von Mutius E., Braun-Fahrlander C., Schierl R., Riedler J., Ehlermann S., Maisch S., Waser M., Nowak D. Exposure to endotoxin or other bacterial components might protect against the development of atopy. Clin Exp Allergy. 30:2000;1230-1234.
21. Von Ehrenstein O.S., Von Mutius E., Illi S., Baumann L., Bohm O., von Kries R. Reduced risk of hay fever and asthma among children of farmers. Clin Exp Allergy. 30:2000;187-193.
22. Slater J.E., Paupore E.J., Elwell M.R., Truscott W. Lipopolysaccharide augments IgG and IgE responses of mice to the latex allergen Hev b 5. J Allergy Clin Immunol. 102:1998;977-983.
23. Reed C., Milton D. Endotoxin-stimulated innate immunity: a contributing factor for asthma. J Allergy Clin Immunol. 108:2001;157-166.
24. Wheeler A.W., Marshall J.S., Ulrich J.T. A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int Arch Allergy Immunol. 126:2001;135-139.
25. Drachenberg K.J., Wheeler A.W., Stuebner P., Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy. 56:2001;498-505.
26. Baldrick P., Richardson D., Wheeler A.W. Safety evaluation of a glutaraldehyde modified tyrosine adsorbed housedust mite extract containing monophosphoryl lipid A (MPL) adjuvant: a new allergy vaccine for dust mite allergy. Vaccine. 20:2001;737-743.
27. Wagner H. Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity. Curr Opin Microbiol. 5:2002;62-69.
28. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 20:2002;709-760.
29. Broide D., Schwarze J., Tighe H., Gifford T., Nguyen M.D., Malek S., Van Uden J., Martin-Orozco E., Gelfand E.W., Raz E. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol. 161:1998;7054-7062.
30. Kline J.N., Waldschmidt T.J., Businga T., Lemish J.E., Weinstock J.V., Thorne P.S., Krieg A.M. Modulation of airway inflammation by Cpg oligodeoxynucleotides in a murine model of asthma. J Immunol. 160:1998;2555-2559.
31. Sur S., Wild J.S., Choudhury B.K., Sur N., Alam R., Klinman D.M. Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J Immunol. 162:1999;6284-6293.
32. Kline J.N., Krieg A.M., Waldschmidt T.J., Ballas Z.K., Jain V., Businga T.R. CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma. J Allergy Clin Immunol. 104:1999;1258-1264.
33. Shirota H., Sano K., Kikuchi T., Tamura G., Shirato K. Regulation of T-helper type 2 cell and airway eosinophilia by transmucosal coadministration of antigen and oligodeoxynucleotides containing CpG motifs. Am J Respir Cell Mol Biol. 22:2000;176-182.
34. Shirota H., Sano K., Kikuchi T., Tamura G., Shirato K. Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator. J Immunol. 164:2000;5575-5582. This is the first report showing that the intratracheal application of CpG-ODN covalently linked to allergen is very efficient in inhibiting allergen-induced Th2 responses. In addition, the authors found that 100-fold less of the conjugate could be used to inhibit the development of Th2 responses compared with giving CpG-ODN alone. These results indicate that vaccines utilising CpG-ODN should use conjugates, as negative side effects associated with increased inflammation after the application of CpG-ODN may be avoided.
35. Tighe H., Takabayashi K., Schwartz D., Van Nest G., Tuck S., Eiden J., Kagey-Sobotka A., Creticos P.S., Lichtenstein L.M., Spiegelberg H.L., Raz E. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol. 106:2000;124-134.
36. Santeliz J.V., Van Nest G., Traquina P., Larsen E., Wills-Karp M. Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J Allergy Clin Immunol. 109:2002;455-462.
37. Shirota H., Sano K., Hirasawa N., Terui T., Ohuchi K., Hattori T., Shirato K., Tamura G. Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells. J Immunol. 167:2001;66-74.
38. Krieg A.M. From A to Z on CpG. Trends Immunol. 23:2002;64-65.
39. Donnelly J.J., Ulmer J.B., Shiver J.W., Liu M.A. DNA vaccines. Annu Rev Immunol. 15:1997;617-648.
40. Hsu C.H., Chua K.Y., Tao M.H., Lai Y.L., Wu H.D., Huang S.K., Hsieh K.H. Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nat Med. 2:1996;540-544.
41. Broide D., Orozco E.M., Roman M., Carson D.A., Raz E. Intradermal gene vaccination down-regulates both arms of the allergic response. J Allergy Clin Immunol. 99:1997;129.
42. Slater J.E., Paupore E., Zhang Y.T., Colberg-Poley A.M. The latex allergen Hev b 5 transcript is widely distributed after subcutaneous injection in BALB/c mice of its DNA vaccine. J Allergy Clin Immunol. 102:1998;469-475.
43. + cells.
44. Li X.M., Chopra R.K., Chou T.Y., Schofield B.H., Wills-Karp M., Huang S.K. Mucosal IFN-gamma gene transfer inhibits pulmonary allergic responses in mice. J Immunol. 157:1996;3216-3239.
45. Kumar M., Behera A.K., Hu J., Lockey R.F., Mohapatra S.S. IFN-gamma and IL-12 plasmid DNAs as vaccine adjuvant in a murine model of grass allergy. J Allergy Clin Immunol. 108:2001;402-408.
46. Hertz M., Mahalingam S., Dalum I., Klysner S., Mattes J., Neisig A., Mouritsen S., Foster P.S., Gautam A. Active vaccination against IL-5 bypasses immunological tolerance and ameliorates experimental asthma. J Immunol. 167:2001;3792-3799. This paper describes a novel DNA vaccination strategy that leads to the reduction of allergen-induced inflammation. The authors used (p)DNA encoding murine IL-5 and modified to contain a foreign Th epitope to protect mice from developing allergen-induced AHR by breaking immunological tolerance to IL-5, resulting in the production of anti-IL-5 antibodies.
47. Lack G., Renz H., Saloga J., Bradley K.L., Loader J., Leung D.Y., Larsen G., Gelfand E.W. Nebulized but not parenteral IFN-gamma decreases IgE production and normalizes airways function in a murine model of allergen sensitization. J Immunol. 152:1994;2546-2554.
48. Lack G., Bradley K.L., Hamelmann E., Renz H., Loader J., Leung D.Y., Larsen G., Gelfand E.W. Nebulized IFN-gamma inhibits the development of secondary allergic responses in mice. J Immunol. 157:1996;1432-1439.
49. Gavett S.H., O'Hearn D.J., Li X., Huang S.K., Finkelman F.D., Wills-Karp M. Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice. J Exp Med. 182:1995;1527-1536.
50. Hofstra C.L., Van Ark I., Hofman G., Kool M., Nijkamp F.P., Van Oosterhout A.J. Prevention of Th2-like cell responses by coadministration of IL-12 and IL-18 is associated with inhibition of antigen-induced airway hyperresponsiveness, eosinophilia, and serum IgE levels. J Immunol. 161:1998;5054-5060.
51. Kumano K., Nakao A., Nakajima H., Hayashi F., Kurimoto M., Okamura H., Saito Y., Iwamoto I. Interleukin-18 enhances antigen-induced eosinophil recruitment into the mouse airways. Am J Respir Crit Care Med. 160:1999;873-878.
52. Wild J.S., Sigounas A., Sur N., Siddiqui M.S., Alam R., Kurimoto M., Sur S. IFN-gamma-inducing factor (IL-18) increases allergic sensitization, serum IgE, Th2 cytokines, and airway eosinophilia in a mouse model of allergic asthma. J Immunol. 164:2000;2701-2710.
53. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., Pulendran B., Palucka K. Immunobiology of dendritic cells. Annu Rev Immunol. 18:2000;767-811.
54. Banchereau J., Schuler-Thurner B., Palucka A.K., Schuler G. Dendritic cells as vectors for therapy. Cell. 106:2001;271-274.
55. Moll H., Berberich C. Dendritic cells as vectors for vaccination against infectious diseases. Int J Med Microbiol. 291:2001;323-329.
56. Ali F.R., Kay A.B., Larche M. The potential of peptide immunotherapy in allergy and asthma. Curr Allergy Asthma Rep. 2:2002;151-158.
57. Boutin Y., Leitenberg D., Tao X., Bottomly K. Distinct biochemical signals characterize agonist- and altered peptide ligand-induced differentiation of naive CD4+ T cells into Th1 and Th2 subsets. J Immunol. 159:1997;5802-5809.
58. Janssen E.M., van Oosterhout A.J., van Rensen A.J., van Eden W., Nijkamp F.P., Wauben M.H. Modulation of Th2 responses by peptide analogues in a murine model of allergic asthma: amelioration or deterioration of the disease process depends on the Th1 or Th2 skewing characteristics of the therapeutic peptide. J Immunol. 164:2000;580-588.
59. Maloy K.J., Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol. 2:2001;816-822.
60. Shevach E.M., McHugh R.S., Piccirillo C.A., Thornton A.M. Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev. 182:2001;58-67.
61. Groux H., O'Garra A., Bigler M., Rouleau M., Antonenko S., de Vries J.E., Roncarolo M.G. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 389:1997;737-742.
62. Hansen G., McIntire J.J., Yeung V.P., Berry G., Thorbecke G.J., Chen L., DeKruyff R.H., Umetsu D.T. CD4(+) T helper cells engineered to produce latent TGF-beta1 reverse allergen-induced airway hyperreactivity and inflammation. J Clin Invest. 105:2000;61-70.
63. Cottrez F., Hurst S.D., Coffman R.L., Groux H. T regulatory cells 1 inhibit a Th2-specific response in vivo. J Immunol. 165:2000;848-853.
64. Haneda K., Sano K., Tamura G., Shirota H., Ohkawara Y., Sato T., Habu S., Shirato K. Transforming growth factor-beta secreted from CD4(+) T cells ameliorates antigen-induced eosinophilic inflammation. A novel high-dose tolerance in the trachea. Am J Respir Cell Mol Biol. 21:1999;268-274.
65. Suto A., Nakajima H., Kagami S.I., Suzuki K., Saito Y., Iwamoto I. Role of CD4(+) CD25(+) regulatory T cells in T helper 2 cell-mediated allergic inflammation in the airways. Am J Respir Crit Care Med. 164:2001;680-687.
66. Borish L., Aarons A., Rumbyrt J., Cvietusa P., Negri J., Wenzel S. Interleukin-10 regulation in normal subjects and patients with asthma. J Allergy Clin Immunol. 97:1996;1288-1296.
67. Koning H., Neijens H.J., Baert M.R., Oranje A.P., Savelkoul H.F. T cells subsets and cytokines in allergic and non-allergic children. II. Analysis and IL-5 and IL-10 mRNA expression and protein production. Cytokine. 9:1997;427-436.
68. Hobbs K., Negri J., Klinnert M., Rosenwasser L., Borish L. Interleukin-10 and transforming growth factor-beta promoter polymorphisms in allergies and asthma. Am J Respir Crit Care Med. 158:1998;1958-1962.
69. van den Biggelaar A.H., van Ree R., Rodrigues L., Lell B., Deelder A.M., Kremsner P.G., Yazdanbakhsh M. Decreased atopy in children infected with Schistosoma haematobium: a role for parasite-induced interleukin-10. Lancet. 356:2000;1723-1727. The authors provide the first evidence that helminth infections may protect humans from allergic disorders by inducing the production of IL-10. The authors speculate that chronic helminth infections induce the development of Tr cells, which inhibit the development of allergic disorders by secreting IL-10.
70. Muller U., Akdis C.A., Fricker M., Akdis M., Blesken T., Bettens F., Blaser K. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol. 101:1998;747-754.
71. Akdis C.A., Blesken T., Akdis M., Wuthrich B., Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest. 102:1998;98-106.
72. Pierkes M., Bellinghausen I., Hultsch T., Metz G., Knop J., Saloga J. Decreased release of histamine and sulfidoleukotrienes by human peripheral blood leukocytes after wasp venom immunotherapy is partially due to induction of IL-10 and IFN-gamma production of T cells. J Allergy Clin Immunol. 102:1999;326-332.
73. Tillie-Leblond I., Pugin J., Marquette C.H., Lamblin C., Saulnier F., Brichet A., Wallaert B., Tonnel A.B., Gosset P. Balance between proinflammatory cytokines and their inhibitors in bronchial lavage from patients with status asthmaticus. Am J Respir Crit Care Med. 159:1999;487-494.
74. Robinson D.S., Tsicopoulos A., Meng Q., Durham S., Kay A.B., Hamid Q. Increased interleukin-10 messenger RNA expression in atopic allergy and asthma. Am J Respir Cell Mol Biol. 14:1996;113-117.
75. Yang X., Wang S., Fan Y., Han X. IL-10 deficiency prevents IL-5 overproduction and eosinophilic inflammation in a murine model of asthma-like reaction. Eur J Immunol. 30:2000;382-391.
76. Makela M.J., Kanehiro A., Borish L., Dakhama A., Loader J., Joetham A., Xing Z., Jordana M., Larsen G.L., Gelfand E.W. IL-10 is necessary for the expression of airway hyperresponsiveness but not pulmonary inflammation after allergic sensitization. Proc Natl Acad Sci USA. 97:2000;6007-6012.
77. Grunig G., Corry D.B., Leach M.W., Seymour B.W., Kurup V.P., Rennick D.M. Interleukin-10 is a natural suppressor of cytokine production and inflammation in a murine model of allergic bronchopulmonary aspergillosis. J Exp Med. 185:1997;1089-1099.
78. Ohno I., Nitta Y., Yamauchi K., Hoshi H., Honma M., Woolley K., O'Byrne P., Tamura G., Jordana M., Shirato K. Transforming growth factor beta 1 (TGF beta 1) gene expression by eosinophils in asthmatic airway inflammation. Am J Respir Cell Mol Biol. 15:1996;404-409.
79. Vignola A.M., Chanez P., Chiappara G., Merendino A., Pace E., Rizzo A., la Rocca A.M., Bellia V., Bonsignore G., Bousquet J. Transforming growth factor-beta expression in mucosal biopsies in asthma and chronic bronchitis. Am J Respir Crit Care Med. 156:1997;591-599.
80. Hellings P.W., Vandenberghe P., Kasran A., Coorevits L., Overbergh L., Mathieu C., Ceuppens J.L. Blockade of CTLA-4 enhances allergic sensitization and eosinophilic airway inflammation in genetically predisposed mice. Eur J Immunol. 32:2002;585-594.
81. Yang J.S., Xu L.Y., Huang Y.M., Van Der Meide P.H., Link H., Xiao B.G. Adherent dendritic cells expressing high levels of interleukin-10 and low levels of interleukin-12 induce antigen-specific tolerance to experimental autoimmune encephalomyelitis. Immunology. 101:2000;397-403.
82. Akbari O., DeKruyf R.H., Umetsu D.T. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol. 2:2001;725-731. This study provides evidence that pulmonary DCs secreting IL-10 are critical for the induction of tolerance induced by the application of antigen into the airways. In addition, the authors provide evidence that these cells induce the development of Tr1 cells.
83. Arkwright P.D., David T.J. Intradermal administration of a killed Mycobacterium vaccae suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease. J Allergy Clin Immunol. 107:2001;531-534. This paper demonstrated for the first time that the application of killed M. vaccae resulted in the improvement of atopic dermatitis in children.
84. Shirtcliffe P.M., Easthope S.E., Cheng S., Weatherall M., Tan P.L., Le Gros G., Beasley R. The effect of delipidated deglycolipidated (DDMV) and heat-killed Mycobacterium vaccae in asthma. Am J Respir Crit Care Med. 163:2001;1410-1414.
85. Barrat F.J., Cua D.J., Boonstra A., Richards D.F., Crain C., Savelkoul H.F., de Waal-Malefyt R., Coffman R.L., Hawrylowicz C.M., O'Garra A. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by Thelper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med. 195:2002;603-616. The authors describe a novel method, using immunosuppressive drugs to generate human and murine Tr cells in vitro. The application of these cells prevented central nervous system inflammation. Using a similar approach, Tr cells could be tested in the immunotherapy of allergic diseases.
86. Hansen G., Berry G., DeKruyff R.H., Umetsu D.T. Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation. J Clin Invest. 103:1999;175-183.
87. Randolph D.A., Carruthers C.J., Szabo S.J., Murphy K.M., Chaplin D.D. Modulation of airway inflammation by passive transfer of allergen-specific Th1 and Th2 cells in a mouse model of asthma. J Immunol. 162:1999;2375-2383.
88. Li L., Xia Y., Nguyen A., Feng L., Lo D. Th2-induced eotaxin expression and eosinophilia coexist with Th1 responses at the effector stage of lung inflammation. J Immunol. 161:1998;3128-3135.
89. Sparwasser T., Miethke T., Lipford G., Borschert K., Hacker H., Heeg K., Wagner H. Bacterial DNA causes septic shock. Nature. 386:1997;336-337.
90. Shimizu J., Yamazaki S., Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 163:1999;5211-5218.
91. Segal B.M., Glass D.D., Shevach E.M. Cutting Edge: IL-10-producing CD4+ T cells mediate tumor rejection. J Immunol. 168:2002;1-4.
92. Actor J.K., Shirai M., Kullberg M.C., Buller R.M., Sher A., Berzofsky J.A. Helminth infection results in decreased virus-specific CD8+ cytotoxic T-cell and Th1 cytokine responses as well as delayed virus clearance. Proc Natl Acad Sci USA. 90:1993;948-952.
93. Borkow G., Leng Q., Weisman Z., Stein M., Galai N., Kalinkovich A., Bentwich Z. Chronic immune activation associated with intestinal helminth infections results in impaired signal transduction and anergy. J Clin Invest. 106:2000;1053-1060.
94. Wong G.W., Hui D.S., Tam C.M., Chan H.H., Fok T.F., Chan-Yeung M., Lai C.K. Asthma, atopy and tuberculin responses in Chinese schoolchildren in Hong Kong. Thorax. 56:2001;770-773.
95. Jentoft H.F., Omenaas E., Eide G.E., Gulsvik A. Absence of relationship between tuberculin reactivity and asthmatic symptoms, level of FEV1 and bronchial hyperresponsiveness in BCG vaccinated young adults. Allergy. 57:2002;336-340.
96. Gruber C., Kulig M., Bergmann R., Guggenmoos-Holzmann I., Wahn U. Delayed hypersensitivity to tuberculin, total immunoglobulin E, specific sensitization, and atopic manifestation in longitudinally followed early Bacille Calmette-Guerin-vaccinated and nonvaccinated children. Pediatrics. 107:2001;346-347.